Clinical Trials Logo

Clinical Trial Summary

A randomised, double blind, placebo controlled parallel study to examine the effects of a dose range of PeptiControl, a plant-based ingredient, in pre-diabetic males and females.


Clinical Trial Description

The primary aim of this study is to evaluate safety and establish the effective dose to see acute effects in males and females with elevated fasting blood glucose. PeptiControl will be supplemented 30 minutes before lunch as a single oral dose of either 2610mg, 870mg or 435mg/day. A placebo group will also be included who will receive microcrystalline cellulose. Capsule number will be matched across all study arms to retain double blinding. This trial incorporates continuous glucose monitoring (CGM) as wearable technology to measure blood glucose and time in range of the participants for the duration of the study. The trial will be conducted over 12 days, which includes a 2 day run-in period to gather baseline CGM data, followed by 6 days of PeptiControl supplementation and 4 days follow up on safety and blood glucose tracking post supplementation. The primary endpoint will measure safety and tolerability via adverse event reporting and occurrence of hypoglycemic episodes evaluated by time below target range (70 - 180 mg/dL) during CGM throughout the intervention. Secondary endpoints investigated during the trial will include safety of a dose range as assessed by a safety blood panel, glucose metabolism and insulin sensitivity, time in range, aspects of cognition and memory and hunger, satiety and fullness as assessed by VAS questionnaires. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06440213
Study type Interventional
Source Nuritas Ltd
Contact Niamh Mohan, PhD
Phone 014301290
Email mohan.niamh@nuritas.com
Status Recruiting
Phase N/A
Start date May 20, 2024
Completion date November 22, 2024

See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Completed NCT02829229 - Community-based Obesity Treatment in African American Women After Childbirth N/A
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A